SQZB Stock Overview
A clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
SQZ Biotechnologies Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.03 |
| 52 Week High | US$0.12 |
| 52 Week Low | US$0.021 |
| Beta | 1.45 |
| 1 Month Change | 0% |
| 3 Month Change | 7.14% |
| 1 Year Change | -15.49% |
| 3 Year Change | -99.43% |
| 5 Year Change | n/a |
| Change since IPO | -99.77% |
Recent News & Updates
Recent updates
SQZ Biotechnologies Company (NYSE:SQZ) Might Not Be As Mispriced As It Looks After Plunging 30%
Jun 26
We Think SQZ Biotechnologies (NYSE:SQZ) Needs To Drive Business Growth Carefully
Jan 05SQZ Biotechnologies GAAP EPS of -$0.77 beats by $0.06, revenue of $3.5M misses by $0.76M
Nov 09SQZ Biotech spikes as H.C. Wainwright initiates with Buy citing platform technology
Oct 20Is SQZ Biotechnologies (NYSE:SQZ) In A Good Position To Deliver On Growth Plans?
Aug 20SQZ Biotechnologies GAAP EPS of -$0.78 misses by $0.01, revenue of $3.22M misses by $0.97M
Aug 04SQZ Biotechnologies names business chief as CFO
Jul 11Time To Worry? Analysts Just Downgraded Their SQZ Biotechnologies Company (NYSE:SQZ) Outlook
May 17Here's Why We're Watching SQZ Biotechnologies' (NYSE:SQZ) Cash Burn Situation
May 02Here's Why We're Watching SQZ Biotechnologies' (NYSE:SQZ) Cash Burn Situation
Jan 11Will SQZ Biotechnologies (NYSE:SQZ) Spend Its Cash Wisely?
Jul 30Need To Know: Analysts Are Much More Bullish On SQZ Biotechnologies Company (NYSE:SQZ)
May 16Newsflash: SQZ Biotechnologies Company (NYSE:SQZ) Analysts Have Been Trimming Their Revenue Forecasts
Mar 25SQZ Biotechnologies Company (NYSE:SQZ) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 20We Think SQZ Biotechnologies (NYSE:SQZ) Can Afford To Drive Business Growth
Feb 01
Shareholder Returns
| SQZB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 2.2% | -2.2% |
| 1Y | -15.5% | -1.9% | 18.3% |
Return vs Industry: SQZB underperformed the US Biotechs industry which returned -1.4% over the past year.
Return vs Market: SQZB underperformed the US Market which returned 20.8% over the past year.
Price Volatility
| SQZB volatility | |
|---|---|
| SQZB Average Weekly Movement | 12.6% |
| Biotechs Industry Average Movement | 10.9% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 17.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: SQZB's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SQZB's weekly volatility has decreased from 49% to 13% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | n/a | n/a | www.sqzbiotech.com |
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents.
SQZ Biotechnologies Company Fundamentals Summary
| SQZB fundamental statistics | |
|---|---|
| Market cap | US$884.73k |
| Earnings (TTM) | -US$71.64m |
| Revenue (TTM) | US$12.12m |
0.1x
P/S Ratio0.0x
P/E RatioIs SQZB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SQZB income statement (TTM) | |
|---|---|
| Revenue | US$12.12m |
| Cost of Revenue | US$51.79m |
| Gross Profit | -US$39.67m |
| Other Expenses | US$31.97m |
| Earnings | -US$71.64m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.43 |
| Gross Margin | -327.29% |
| Net Profit Margin | -591.07% |
| Debt/Equity Ratio | 0% |
How did SQZB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/22 10:16 |
| End of Day Share Price | 2025/02/20 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
SQZ Biotechnologies Company is covered by 7 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tazeen Ahmad | BofA Global Research |
| Leah Rush Cann | Brookline Capital Markets |
| Thomas Shrader | BTIG |